PharmaCyte Biotech (PMCB) Enterprise Value (2012 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Enterprise Value of -$18.9 million for Q2 2026, down 21.36% year-over-year from -$24.0 million in Q2 2025, and up 8.18% quarter-over-quarter from -$20.5 million in Q1 2026.
PharmaCyte Biotech (PMCB) Enterprise Value (2012 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Enterprise Value for 15 consecutive years, with -$18.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 21.36% year-over-year to -$18.9 million; the TTM figure through Apr 2026 stood at -$18.9 million (down 21.36% YoY), while the FY2026 annual figure was -$18.9 million, down 21.36% from the prior year.
- Enterprise Value rose to -$18.9 million in Q2 2026 per PMCB's latest filing, from -$20.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$13.4 million in Q3 2025 and bottomed at -$86.6 million in Q1 2022.
- Historically, Enterprise Value has averaged -$49.2 million across 5 years, with a median of -$55.7 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value tumbled 8471.89% — and 2025, when it jumped 72.63%.
- PharmaCyte Biotech's Enterprise Value stood at -$77.0 million in 2022, then grew by 4.6% to -$73.4 million in 2023, then surged by 71.62% to -$20.8 million in 2024, then grew by 25.11% to -$15.6 million in 2025, then retreated by 20.83% to -$18.9 million in 2026.
- Business Quant data shows PMCB's Enterprise Value at -$18.9 million in Q2 2026, -$20.5 million in Q1 2026, and -$15.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 2.12 Bn |
| 10 | PharmaCyte Biotech | 4.44 Mn | 4.44 Mn | - | -18.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -18.86 Mn |
| Jan 31, 2026 | -20.54 Mn |
| Oct 31, 2025 | -15.61 Mn |
| Jul 31, 2025 | -13.44 Mn |
| Apr 30, 2025 | -15.54 Mn |
| Jan 31, 2025 | -16.76 Mn |
| Oct 31, 2024 | -20.84 Mn |
| Jul 31, 2024 | -32.64 Mn |
| Apr 30, 2024 | -50.18 Mn |
| Jan 31, 2024 | -61.21 Mn |
| Oct 31, 2023 | -73.43 Mn |
| Jul 31, 2023 | -74.66 Mn |
| Apr 30, 2023 | -68.04 Mn |
| Jan 31, 2023 | -72.64 Mn |
| Oct 31, 2022 | -76.96 Mn |
| Jul 31, 2022 | -82.23 Mn |
| Apr 30, 2022 | -85.40 Mn |
| Jan 31, 2022 | -86.64 Mn |
| Oct 31, 2021 | -86.94 Mn |
| Jul 31, 2021 | -959,270.00 |